JP2015517463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517463A5 JP2015517463A5 JP2015510278A JP2015510278A JP2015517463A5 JP 2015517463 A5 JP2015517463 A5 JP 2015517463A5 JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015517463 A5 JP2015517463 A5 JP 2015517463A5
- Authority
- JP
- Japan
- Prior art keywords
- candidate compounds
- aureus infection
- cd11b
- lukab
- aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 70
- 208000015181 infectious disease Diseases 0.000 claims description 62
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 49
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- 230000009261 transgenic effect Effects 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000003013 cytotoxicity Effects 0.000 claims description 14
- 231100000135 cytotoxicity Toxicity 0.000 claims description 14
- 210000000265 leukocyte Anatomy 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000034994 death Effects 0.000 claims description 11
- 231100000517 death Toxicity 0.000 claims description 11
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 8
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims description 8
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 7
- 229960003085 meticillin Drugs 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 206010040872 skin infection Diseases 0.000 claims description 3
- -1 3,4-dihydro-2H-quinolin-1-yl Chemical group 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 101710170970 Leukotoxin Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641543P | 2012-05-02 | 2012-05-02 | |
| US61/641,543 | 2012-05-02 | ||
| PCT/US2013/032436 WO2013165613A1 (en) | 2012-05-02 | 2013-03-15 | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517463A JP2015517463A (ja) | 2015-06-22 |
| JP2015517463A5 true JP2015517463A5 (enExample) | 2016-04-21 |
Family
ID=49514732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510278A Pending JP2015517463A (ja) | 2012-05-02 | 2013-03-15 | 黄色ブドウ球菌感染および関連状態を処置および予防する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9657103B2 (enExample) |
| EP (1) | EP2844287A4 (enExample) |
| JP (1) | JP2015517463A (enExample) |
| CN (1) | CN104428000A (enExample) |
| AU (1) | AU2013257161B2 (enExample) |
| CA (1) | CA2871152A1 (enExample) |
| HK (1) | HK1207981A1 (enExample) |
| IL (1) | IL235284A0 (enExample) |
| WO (1) | WO2013165613A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014270598B2 (en) * | 2013-05-21 | 2018-09-20 | Arsanis Biosciences Gmbh | Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| CN108135961A (zh) * | 2015-06-12 | 2018-06-08 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 调控免疫反应的方法及多肽 |
| CN110913883A (zh) * | 2017-06-13 | 2020-03-24 | 综合生物治疗疫苗公司 | 包含金黄色葡萄球菌杀白细胞素luka和lukb来源的多肽的免疫原性组合物 |
| US12291562B2 (en) | 2019-04-01 | 2025-05-06 | Rush University Medical Center | Reagents and assays using modified integrin domains |
| CN114437187B (zh) * | 2022-02-09 | 2023-06-20 | 淮北师范大学 | 一种细菌素Bacin A4及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| US20030162956A1 (en) * | 1997-04-07 | 2003-08-28 | Human Genome Sciences, Inc. | Leukocyte regulatory factors 1 and 2 |
| JP2004504827A (ja) * | 2000-07-31 | 2004-02-19 | ザ ジェネラル ホスピタル コーポレーション | 高親和性インテグリンポリペプチドおよびその使用方法 |
| US7323552B2 (en) * | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
| WO2004020601A2 (en) * | 2002-08-28 | 2004-03-11 | University Of Florida | Neurogenesis from hepatic stem cells |
| JP2006094701A (ja) * | 2002-09-17 | 2006-04-13 | Chugai Pharmaceut Co Ltd | ７ｆ４遺伝子トランスジェニック動物 |
| JP4897690B2 (ja) * | 2004-10-12 | 2012-03-14 | ジェネンテック， インコーポレイテッド | 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド |
| WO2006086500A2 (en) * | 2005-02-08 | 2006-08-17 | Aspreva Pharmaceuticals Sa | Compositions and methods for treating vascular, autoimmune and inflammatory diseases |
| JP2008537478A (ja) * | 2005-02-24 | 2008-09-18 | ザ・スクリプス・リサーチ・インステイチユート | 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法 |
| JP5250810B2 (ja) * | 2006-05-31 | 2013-07-31 | 公益財団法人ヒューマンサイエンス振興財団 | ユートロフィン遺伝子発現増強物質のスクリーニング |
| JP2008220174A (ja) * | 2007-03-08 | 2008-09-25 | Tokyoto Igaku Kenkyu Kiko | 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物 |
| US20100310665A1 (en) | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| EP4219560A3 (en) * | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
| HUE058787T2 (hu) * | 2010-05-05 | 2022-09-28 | Univ New York | Staphylococcus aureus leukocidinek, terápiás készítmények és azok felhasználása |
| US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| MX343589B (es) * | 2011-06-19 | 2016-11-11 | Univ New York | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. |
| CN103717234A (zh) | 2011-06-19 | 2014-04-09 | 纽约大学 | 治疗和预防金黄色葡萄球菌感染及相关病状的方法 |
-
2013
- 2013-03-15 US US14/398,293 patent/US9657103B2/en not_active Expired - Fee Related
- 2013-03-15 WO PCT/US2013/032436 patent/WO2013165613A1/en not_active Ceased
- 2013-03-15 HK HK15108668.7A patent/HK1207981A1/xx unknown
- 2013-03-15 EP EP13784426.2A patent/EP2844287A4/en not_active Withdrawn
- 2013-03-15 JP JP2015510278A patent/JP2015517463A/ja active Pending
- 2013-03-15 CA CA2871152A patent/CA2871152A1/en not_active Abandoned
- 2013-03-15 CN CN201380034208.9A patent/CN104428000A/zh active Pending
- 2013-03-15 AU AU2013257161A patent/AU2013257161B2/en not_active Ceased
-
2014
- 2014-10-22 IL IL235284A patent/IL235284A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grousd et al. | Host-pathogen interactions in gram-positive bacterial pneumonia | |
| JP2015517463A5 (enExample) | ||
| Lupfer et al. | Receptor interacting protein kinase 2–mediated mitophagy regulates inflammasome activation during virus infection | |
| Traub et al. | An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation | |
| Gu et al. | Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus | |
| Pinar et al. | PB1-F2 peptide derived from avian influenza A virus H7N9 induces inflammation via activation of the NLRP3 inflammasome | |
| Zhou et al. | Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis | |
| Koch et al. | Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b | |
| Lin et al. | Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction | |
| Watkins et al. | Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus | |
| Agrawal et al. | Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection | |
| Pincus et al. | Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection | |
| Keynan et al. | Staphylococcus aureus bacteremia, risk factors, complications, and management | |
| Gunn et al. | Mannose binding lectin is required for alphavirus-induced arthritis/myositis | |
| Wang et al. | Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self‐assembly of α‐hemolysin | |
| Josefsson et al. | Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence | |
| Peng et al. | Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer | |
| Wang et al. | Interaction of fibrinogen and muramidase-released protein promotes the development of Streptococcus suis meningitis | |
| Basso et al. | Fungicidal potency and mechanisms of θ-defensins against multidrug-resistant Candida species | |
| Seo et al. | Role of the serine-rich surface glycoprotein Srr1 of Streptococcus agalactiae in the pathogenesis of infective endocarditis | |
| Hong et al. | Staphylococcal protein A promotes colonization and immune evasion of the epidemic healthcare-associated MRSA ST239 | |
| Bidula et al. | Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species | |
| Choy et al. | The multifunctional LigB adhesin binds homeostatic proteins with potential roles in cutaneous infection by pathogenic Leptospira interrogans | |
| Safronetz et al. | In vitro and in vivo activity of ribavirin against Andes virus infection | |
| Smalley et al. | Rickettsia australis activates inflammasome in human and murine macrophages |